Quantcast

Wound Healing Partnering 2009-2014

August 4, 2014

LONDON, Aug. 4, 2014 /PRNewswire/ — Reportbuyer.com has added a new market research report: Wound Healing Partnering 2009-2014

http://www.reportbuyer.com/pharma_healthcare/medical_supplies/hospital_supplies/wound_healing_partnering_2007_2013.html

The report will be delivered in PDF format within 3 working days of receipt of order. If print or CD-Rom version purchased, the report will be sent by courier using express service.

Wound Healing Partnering 2009-2014 report provides understanding and access to the wound healing partnering deals and agreements entered into by the worlds leading healthcare companies.

    --  Trends in wound healing partnering deals
    --  Top wound healing deals by value
    --  Deals listed by company A-Z, industry sector, stage of development,
        technology type

Wound Healing Partnering 2009-2014 provides understanding and access to the wound healing partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an analysis of wound healing partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors wound healing technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This data driven report contains over 236 links to online copies of actual liver disease deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of HIV partnering trends.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in wound healing partnering since 2009, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.

Chapter 3 provides an overview of the leading wound healing deals since 2009. Deals are listed by headline value, signed by bigpharma, most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive directory of wound healing partnering deals signed and announced since 2009. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of wound healing technologies and products.

Report scope

Wound Healing Partnering 2009-2014 is intended to provide the reader with an in-depth understanding and access to wound healing trends and structure of deals entered into by leading companies worldwide.

This data driven report includes:

    --  Trends in wound healing dealmaking in the biopharma industry since 2009
    --  Access to summary headline, upfront, milestone and royalty data
    --  The leading wound healing deals by value since 2009

In Wound Healing Partnering 2009-2014, the available deals are listed by:

    --  Headline value
    --  Upfront payment value
    --  Royalty rate value
    --  Company A-Z
    --  Industry sector
    --  Stage of development at signing
    --  Deal component type
    --  Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Wound Healing Partnering 2009-2014 provides the reader with the following key benefits:

    --  In-depth understanding of wound healing deal trends since 2009
    --  Access to summary headline, upfront, milestone and royalty data
    --  Comprehensive access to over 230 actual wound healing deals entered into
        by the world's biopharma companies since 2009
    --  Insight into key deal terms included in contracts, where disclosed
    --  Understand the key deal terms companies have agreed in deals
    --  Undertake due diligence to assess suitability of your proposed deal
        terms for partner companies

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in wound healing partnering

    --  2.1. Introduction
    --  2.2. Wound healing partnering over the years
    --  2.3. Bigpharma wound healing dealmaking activity
    --  2.4. Wound healing partnering by deal type
    --  2.5. Wound healing partnering industry sector
    --  2.6. Wound healing partnering by stage of development
    --  2.7. Wound healing partnering by technology type
    --  2.8. Disclosed financial deal terms for wound healing partnering
    --  2.8.1 Wound healing headline values
    --  2.8.2 Wound healing upfront payments
    --  2.8.3 Wound healing milestone payments
    --  2.8.4 Wound healing royalty rates

Chapter 3 – Leading wound healing deals

    --  3.1. Introduction
    --  3.2. Top wound healing deals by value
    --  3.3. Top wound healing deals involving bigpharma

Chapter 4 – Dealmaking directory

    --  4.1. Introduction
    --  4.2. Company A-Z
    --  4.3. By deal type
    --  Asset purchase
    --  Bigpharma outlicensing
    --  Co-development
    --  Collaborative R&D
    --  Co-market
    --  Contract service
    --  Co-promotion
    --  CRADA
    --  Cross-licensing
    --  Development
    --  Distribution
    --  Equity purchase
    --  Evaluation
    --  Grant
    --  Joint venture
    --  Licensing
    --  Manufacturing
    --  Marketing
    --  Option
    --  Promotion
    --  Research
    --  Settlement
    --  Spin out
    --  Sub-license
    --  Supply
    --  Termination
    --  4.4. By industry sector
    --  Academic
    --  Bigpharma
    --  Biotech
    --  Drug delivery
    --  Medical device
    --  Diagnostic
    --  Generic pharma
    --  Government
    --  Non-profit
    --  Pharmaceutical
    --  Research tools
    --  Services
    --  Specialty pharma
    --  4.5. By stage of development
    --  Discovery
    --  Pre-clinical
    --  Phase I
    --  Phase II
    --  Phase III
    --  Registration
    --  Marketed
    --  4.6. By technology type
    --  Analysis
    --  Animal models
    --  Assays
    --  Bioinformatics
    --  Biological compounds
    --  Biomarkers
    --  Biomaterials
    --  Cell culture
    --  Cell therapy
    --  Clinical testing
    --  Diagnostic - companion
    --  Devices
    --  Diagnostics
    --  Discovery tools
    --  DNA probes
    --  Drug delivery
    --  Enabling technology
    --  Epigenetics
    --  Equipment
    --  Facilities
    --  Gene therapy
    --  Genomics
    --  Imaging
    --  Industrial chemicals
    --  In vitro models
    --  Monoclonal antibodies
    --  Nanotechnology
    --  Oligonucleotide
    --  Peptides
    --  Personalised medicine
    --  Processes
    --  Proteomics
    --  Radio/Chemo-therapy
    --  Recombinant DNA
    --  Research services
    --  Research supplies
    --  RNA therapeutics
    --  Screening
    --  Small molecules
    --  Stem cells
    --  Vaccines

Chapter 5 – Partnering resource center

    --  --5.1. Online partnering
    --  --5.2. Partnering events
    --  --5.3. Further reading on dealmaking

Appendices

    --  Appendix 1 - Deal type definitions
    --  About Wildwood Ventures
    --  Current Partnering
    --  Current Agreements
    --  Recent titles from CurrentPartnering
    --  Order Form - Reports

Table of figures

    --  Figure 1: Wound healing partnering since 2009
    --  Figure 2: Bigpharma - top 50 - wound healing deals 2009 to 2014
    --  Figure 3: Bigpharma wound healing deal frequency - 2009 to 2014
    --  Figure 4: Wound healing partnering by deal type since 2009
    --  Figure 5: Wound healing partnering by industry sector since 2009
    --  Figure 6: Wound healing partnering by stage of development since 2009
    --  Figure 7: Wound healing partnering by technology type since 2009
    --  Figure 8: Wound healing deals with a headline value
    --  Figure 9: Wound healing deals with upfront payment values
    --  Figure 10: Wound healing deals with milestone payments
    --  Figure 11: Wound healing deals with royalty rates, %
    --  Figure 12: Top wound healing deals by value since 2009
    --  Figure 13: Top wound healing deals signed by bigpharma value since 2009
    --  Figure 14: Online partnering resources
    --  Figure 15: Forthcoming partnering events
    --  Figure 16: Deal type definitions

Read the full report:

Wound Healing Partnering 2009-2014

http://www.reportbuyer.com/pharma_healthcare/medical_supplies/hospital_supplies/wound_healing_partnering_2007_2013.html

For more information:

Sarah Smith

Research Advisor at Reportbuyer.com

Email: query@reportbuyer.com

Tel: +44 208 816 85 48

Website: www.reportbuyer.com


Source: PR Newswire



comments powered by Disqus